Eli Lilly has announced plans to expand its domestic medicine production in the US by establishing four new pharmaceutical manufacturing sites.
The move increases the company’s total US capital expansion commitments to more than $50bn since 2020.
Go deeper with GlobalData
Three of the four sites will concentrate on active pharmaceutical ingredients manufacturing, aiming to reshore essential small molecule chemical synthesis capabilities and reinforce the company’s supply chain.
The last site will add to Lilly’s international network for parenteral manufacturing, catering to future injectable treatments.
The construction phase will generate around 10,000 jobs and new facilities will employ 3,000 skilled professionals such as operations staff, scientists, lab technicians and engineers.
The new sites will bring substantial economic benefits to their respective communities, including increased local spending, economic diversification, enhanced infrastructure, tax revenue and opportunities for training and development.
Lilly manufacturing operations president and executive vice-president Edgardo Hernandez stated: “To deliver on our big bets on next-generation modalities like small molecules, biologics and nucleic acid therapies, Lilly is investing in the state-of-the-art manufacturing infrastructure needed to deliver tomorrow’s safe and reliable medicines.
“We are not just building facilities. We are creating a future where American innovation leads the world in pharmaceutical manufacturing, requiring a highly skilled workforce prepared to shape the future of health care.”
Between 2020 and 2024, Lilly committed $23bn to domestic capital expansion, which is represented in the $50bn announcement.
The commitments included investments in locations such as Research Triangle Park and Concord in North Carolina, updates to several Indianapolis facilities, the LEAP Innovation District and Lilly Medicine Foundry, both in Lebanon, Indiana, and the acquisition and expansion of a manufacturing site in Kenosha County, Wisconsin.
In August 2024, the company opened the research and development hub, Lilly Seaport Innovation Center, in Boston’s Seaport district, US.
